A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
Clinical trial NCT03207009 · COMPLETED
Trial details
- NCT number
- NCT03207009
- Sponsor
- Genetix Biotherapeutics Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-08
- Primary completion
- 2022-11-15
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.